LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear

Sponsor
Szabocsik and Associates, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT01735045
Collaborator
(none)
76
5
2
20
15.2
0.8

Study Details

Study Description

Brief Summary

This study is to evaluate the performance of the LSH (mangofilcon A) silicone hydrogel soft contact lenses when used as a daily wear contact lens for the correction of myopia.

Condition or Disease Intervention/Treatment Phase
  • Device: Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens
  • Device: Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
76 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear
Study Start Date :
May 1, 2010
Actual Primary Completion Date :
Dec 1, 2011
Actual Study Completion Date :
Jan 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Test Group myopia control

Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control

Device: Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens
Daily Wear

Active Comparator: Myopia Control

Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control

Device: Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens

Outcome Measures

Primary Outcome Measures

  1. Visual Acuity [3 months]

    Snelling Scale

Secondary Outcome Measures

  1. Slit Lamp Findings [3 months]

    Grading by the Slit Lamp Classification Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Have been advised that the contact lenses they will be wearing for the next 3 months are being used for investigational purposes and that their informed consent will be needed and documented prior to the start of the study.

  • Visual acuity must be correctable to 20/30, with spherical lenses ranging in power from -1.00 to -5.00D, astigmatism≤1.50D.

  • Have been successfully wearing soft (hydrophilic) contact lenses for at least one month prior to entering the study. (Success means both subject and practitioner are satisfied with visual acuity, comfort, and ocular physiology).

  • Have non-diseased eyes which are normal or which have no preexisting ocular condition which would interfere with the patient's ability to adapt to the new pair of LSH Silicone Hydrogel Soft (hydrophilic) Contact Lenses. A normal eye is defined as one having all the following characteristics:

  1. No evidence of lid infection.

  2. No structural lid abnormality.

  3. No conjunctival abnormality or infection.

  4. A cornea which is clear with no edema, staining, vascularization or abnormal opacities, all as observed by slit lamp examination.

  5. No iritis.

  6. No other active ocular disease that would contraindicate use of the investigational lens.

  7. No GPC (giant papillary conjunctivitis, tarsal abnormality) Grade 2 or greater

  • Use no ocular medication.

  • Have no known sensitivity to solutions currently used for contact lens care.

  • Have binocular correction with contact lenses.

Exclusion Criteria

  • Astigmatism >1.50D

  • No monocular or monovision fits may be included.

  • Pregnant and lactating women are excluded from the study

  • Minors (under age 18) are excluded from the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Glenda Secor, OD Huntington Beach California United States 92647
2 Randall Sakamoto Honolulu Hawaii United States 96814
3 Robert Davis, OD Oak Lawn Illinois United States 60453
4 Douglas P. Benoit, OD, FAAO Concord New Hampshire United States 03301
5 Stephen P. Byrnes, OD, FAAO Londonderry New Hampshire United States 03053

Sponsors and Collaborators

  • Szabocsik and Associates, Inc.

Investigators

  • Study Director: John M Szabocsik, PhD,

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Szabocsik and Associates, Inc.
ClinicalTrials.gov Identifier:
NCT01735045
Other Study ID Numbers:
  • HF-2010-01
First Posted:
Nov 28, 2012
Last Update Posted:
Nov 28, 2012
Last Verified:
Nov 1, 2012
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 28, 2012